Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
AUSTIN, TX—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), recently sold 1,632 shares of the company’s common stock, totaling approximately $290,120. The shares were sold on February 6, 2025, at a price of $177.77 per share. The transaction comes as Natera, now valued at $22.8 billion, trades near its 52-week high of $183, having delivered an impressive 148% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value.
This transaction was part of a plan to fulfill tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). These RSUs were initially granted to Moshkevich on October 22, 2021, and January 28, 2022, with vesting tied to specific time and performance criteria. The criteria for vesting were certified on February 5, 2025, allowing for the acquisition and subsequent sale of shares.
Following these transactions, Moshkevich holds a total of 149,768 shares in Natera.
In other recent news, Natera Inc . has been making notable strides in the medical field. Following the release of positive study results related to the company’s Signatera test, Canaccord Genuity maintained a Buy rating for Natera. The firm’s analysts expressed optimism about Natera’s participation in two significant clinical colorectal cancer studies, highlighting the potential of Signatera in the MRD testing space.
Moreover, Barclays (LON:BARC) initiated coverage on Natera shares with an Overweight rating. The firm’s analyst, Luke Sergott, cited Natera’s expansion into new markets and its first-mover advantage in the MRD space as reasons for the positive outlook. TD Cowen also showed confidence in Natera’s future performance by increasing the company’s price target from $175.00 to $195.00, maintaining a Buy rating.
Additionally, Natera has broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc., involving the RaDaR assay. The District Court for the Middle District of North Carolina allowed the inclusion of an additional patent in the ongoing lawsuit. The company is seeking comprehensive remedies, including injunctive relief against NeoGenomics’ current RaDaR test offering.
In other developments, Natera announced an updated employment agreement with Dr. Matthew Rabinowitz, its Executive Chairman and Co-Founder. The new contract revises the terms of the prior agreement, adjusting the annual base salary and outlining potential bonuses and equity awards. These are recent developments that provide investors with highlights from the recent news about Natera.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.